Is e.l.f. Beauty Stock a Buy as Rhode Drives Growth?

E.l.f. Beauty reported Q4 revenue of $449.3 million, up 35% year over year and ahead of the $423 million consensus, while adjusted EPS of $0.32 also beat estimates despite a 59% decline from last year. Rhode contributed $113 million in quarterly revenue and $390 million for the fiscal year, offsetting weakness in the namesake brand, where unit volume fell after a price increase. Management guided fiscal 2027 revenue to $1.835 billion-$1.865 billion, up 14%-17%, and sees adjusted EPS rising to $3.27-$3.32, with tariffs expected to ease from 55% to 35%.

Analysis

ELF is becoming a two-speed story: the acquisition-led skincare engine is masking a deteriorating core brand economics problem. That matters because mix can look flattering for several quarters while underlying unit elasticity quietly worsens; if price cuts restore volume in the namesake line, the main question is whether that volume is incremental or merely recaptured demand at lower margin. The market is likely underappreciating how quickly a prestige-adjacent brand can re-rate when distribution expands in Europe, but the flip side is that any stumble on execution will hit the stock multiple hard because the valuation is already discounting sustained growth.

The second-order beneficiary is Sephora/LVMH distribution rather than just ELF itself: a successful European rollout should reinforce the retailer’s role as a gatekeeper for fast-scaling skincare and could crowd out weaker challenger brands with less marketing firepower. Competitively, lower prices on the mass color cosmetics side could force peers with similar price architecture to defend share, potentially squeezing category margins for smaller brands that lack ELF’s procurement scale. The tariff improvement is also more important than it looks because it creates optionality: management can either protect gross margin or spend it into price/value repositioning, and the latter would likely be more accretive to long-term share gains than near-term EPS.

The main risk is that the market extrapolates Rhode’s trajectory too linearly. Freshness fades, distribution expansion lags, and beauty demand is notoriously promotional once growth slows; if organic growth remains negative into the next two quarters, the stock can de-rate before the European launch benefits arrive. The contrarian setup is that consensus may be too focused on headline EPS compression and not enough on the operating leverage embedded in a successful price reset plus rollout cadence, which creates a 6-12 month upside window if unit trends stabilize by summer.

This is a reasonable long, but the better expression is a time-bounded trade rather than a permanent compounder bet. The upside case is multiple expansion off a cheap growth valuation if Rhode and Naturium keep comping and the core brand volume troughs; the downside case is that ELF proves it can grow revenue only by buying sales with marketing and discounting. That asymmetry argues for buying on pullbacks, not chasing strength after the report.

Key Decisions for Investors

• Long ELF for a 6-9 month horizon on weakness below the post-earnings range; target a re-rating toward mid-teens revenue growth credibility, with upside driven by Rhode distribution and tariff-driven pricing flexibility.
• For more convex exposure, buy ELF Jan-2027 call spreads funded on dips; the setup is a low-to-mid P/E growth multiple where execution upside can expand the multiple faster than earnings grow.
• Pair trade: long ELF / short a basket of slower-growth beauty peers with similar premium-to-mass exposure, expressing the view that Rhode and Naturium take share while weaker brands absorb promotional pressure over the next 2-3 quarters.
• If core-brand units remain negative into the next two prints, cut ELF exposure by half; the market will likely punish any evidence that growth is still acquisition-dependent rather than organically broad-based.